David P. Luci Purchases 49,261 Shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Stock

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) CEO David P. Luci acquired 49,261 shares of the business’s stock in a transaction on Monday, January 6th. The shares were bought at an average price of $1.01 per share, with a total value of $49,753.61. Following the completion of the transaction, the chief executive officer now directly owns 1,097,458 shares of the company’s stock, valued at approximately $1,108,432.58. The trade was a 4.70 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Acurx Pharmaceuticals Stock Performance

ACXP stock opened at $0.75 on Friday. Acurx Pharmaceuticals, Inc. has a 52 week low of $0.68 and a 52 week high of $5.28. The company has a market capitalization of $12.69 million, a PE ratio of -0.69 and a beta of -1.71. The company’s 50-day simple moving average is $1.17 and its 200 day simple moving average is $1.77.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. During the same quarter last year, the business posted ($0.24) EPS. On average, analysts forecast that Acurx Pharmaceuticals, Inc. will post -0.89 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Acurx Pharmaceuticals in a report on Tuesday, December 10th.

Hedge Funds Weigh In On Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Geode Capital Management LLC increased its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 12.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 146,500 shares of the company’s stock after purchasing an additional 16,485 shares during the period. Geode Capital Management LLC owned approximately 0.90% of Acurx Pharmaceuticals worth $278,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.